Results 241 to 250 of about 47,580 (341)

Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells

Advanced Science, Volume 13, Issue 5, 27 January 2026.
This study demonstrates that tumor‐derived IL‐35 promotes pancreatic cancer fibrosis by indirectly activating pancreatic stellate cells through IGFBP2/IGF‐1R/PI3K‐Akt and Tsp‐1/TGF‐β pathways. IL‐35 blockade reduces stromal fibrosis, restores chemosensitivity, and synergizes with gemcitabine‐based regimens, highlighting IL‐35 as a promising therapeutic
Hui Li, Huizhi Sun, Jing Liu, Yan Wu, Lin Wei, Jianming Li, Yudong Yuan, Peng Xie, Chao Xu, Guolu Luo, Yuqi Guan, Yukuan Feng, Antao Chang, Jihui Hao, Chongbiao Huang   +14 more
wiley   +1 more source

Design and development of a bispecific antibody targeting BAFF and IL-17 for systemic lupus erythematosus treatment. [PDF]

BMC Biol
Xin C, Zhou J, Chen Y, Liu Y, Liu H, Liang C, Zhu X, Qi Y, Zhang G, Wang A.   +9 more
europepmc   +1 more source

BRIGHT Enables High‐SNR Live‐Cell Imaging of Non‐Repetitive Sequences via Bivalent Fluorescent Nanobody‐Mediated Cascade‐Dependent Illumination

Advanced Science, Volume 13, Issue 2, 9 January 2026.
BRIGHT is a newly developed live‐cell imaging system that integrates cascade amplification with background denoising through the bivalent binding capability and antigen‐dependent stability of a bivalent fluorescent nanobody targeting ALFA peptides.
Lei Feng, Tao Huang, Yanxi Han, Meng Tian, Duo Wang, Zilong Mei, Yu Ma, Yingshuo Ma, Jinming Li, Rui Zhang   +9 more
wiley   +1 more source

Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort. [PDF]

Br J Haematol
Noveihed A, Al Hadidi S, Mohan M, Shah MR.   +3 more
europepmc   +1 more source

Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy

American Journal of Hematology, Volume 101, Issue 1, Page 56-69, January 2026.
Disease‐specific, patient‐specific, and treatment‐related factors correlate with renal recovery. ABSTRACT Acute renal failure due to cast nephropathy (CAN) is a severe complication of multiple myeloma (MM). Here, we aimed to identify parameters associated with renal outcomes and survival in newly diagnosed MM patients with CAN‐related acute renal ...
Heinz Ludwig, Meletios Athanasios Dimopoulos, Evangelos Terpos, Sarah Bernhard, Foteini Theodorakakou, Meral Beksac, Guldane Cengiz‐Seval, Nelson Leung, Luca Arcaini, Silvia Mangiacavalli, Frank Bridoux, Hermine Agis, Aristeidis Chaidos, Francesca Gay, Dario Roccatello, Wolfgang Hilbe, Andrea Havasi, Daniele Derudas, Nattawat Klomjit, Kenar D. Jhaveri, Javier De La Rubia Comos, Efstathios Kastritis   +21 more
wiley   +1 more source

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer. [PDF]

J Transl Med
Greiner SM, Mauermann J, Lutz MS, Hagelstein I, Hartkopf AD, Zekri L, Jung G, Salih HR, Märklin M.   +8 more
europepmc   +1 more source

Inducible T‐Cell Co‐Stimulator (ICOS) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

Cancer Medicine, Volume 15, Issue 1, January 2026.
ICOS (inducible T‐cell co‐stimulator) and ICOS ligand (ICOSL) are part of an important, complex pathway that can lead to both immune stimulation and suppression. Both ICOS agonists and antagonists are under development as oncology therapeutics and biomarker driven approaches will be important to ascertain which patients will derive the greatest benefit
Mina Nikanjam, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Sarabjot Pabla, Mary K. Nesline, Heidi Ko, Jeffrey M. Conroy, Aung Naing, Razelle Kurzrock   +9 more
wiley   +1 more source

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma. [PDF]

Blood Cancer J
Ng LCK, Lee XH, Tan YC, Wong KL, Chow JCY, Ling VWT, Thong EWS, Chan EHL, Chan WL, Samuel M, Poon MLM.   +10 more
europepmc   +1 more source

A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications [PDF]

Shuang Wang, Weijie Zhang, Baotian Yang, Xudong Zhang, Jing Fang, Haopeng Rui, Zhijian Chen, Jijie Gu, Zhiqiang Chen, Jianqing Xu   +9 more
openalex   +1 more source

Real‐World Outcomes of Polatuzumab Vedotin Plus R‐CHP Versus R‐CHOP‐Based Regimens in Japanese Patients With Untreated Diffuse Large B‐Cell Lymphoma

Cancer Medicine, Volume 15, Issue 1, January 2026.
PV‐R‐CHP showed improved progression‐free and overall survivals compared to R‐CHOP‐based regimens in newly diagnosed Japanese patients with DLBCL, particularly in those with non‐GCB subtype. These results were consistent in both the overall cohort and propensity score‐matched cohorts.
Masaaki Hotta, Atsushi Satake, Ayako Iwama, Tokiko Hoshiyama, Yukie Tsubokura, Hideaki Yoshimura, Shinya Fujita, Yumiko Kono, Tomoki Ito   +8 more
wiley   +1 more source